Metastatic human epidermal growth factor receptor 2-positive breast cancer: Management, challenges, and future directions

被引：3

作者：

Soleja, Mohsin ^{[1
]}

Rimawi, Mothaffar F.

机构：

[1] Baylor Coll Med, Dept Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA

来源：

CURRENT PROBLEMS IN CANCER | 2016年 / 40卷 / 2-4期

关键词：

Metastatic breast cancer; HER2; Trastuzumab; Pertuzumab; T-DM1; Lapatinib; Resistance; Management; Novel therapy; TUMOR-INFILTRATING LYMPHOCYTES; LAPATINIB PLUS CAPECITABINE; NERVOUS-SYSTEM METASTASES; BRAIN METASTASES; DOUBLE-BLIND; TRASTUZUMAB EMTANSINE; PROTEIN EXPRESSION; ESTROGEN-RECEPTOR; PHASE-III; TAMOXIFEN RESISTANCE;

D O I：

10.1016/j.currproblcancer.2016.09.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

HER2 is over-expressed or amplified in 15-20% of breast cancer. Significant progress has been made in the treatment of metastatic HER2+ breast cancer. This is largely due to successful targeting of the HER2 pathway. There are several approved agents in the metastatic setting. However, treatment resistance frequently develops and tumors eventually progress. In recent years, our understanding of mechanisms of resistance has evolved. It is generally accepted now that HER2-positive breast cancer is not one disease. New therapeutic strategies and a tailored approach to management are necessary to maximize patient outcomes and minimize toxicity. (C) 2016 Elsevier Inc. All rights reserved.

引用

页码：117 / 129

页数：13

共 90 条

[1] Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199 [J].

Adams, Sylvia ;

Gray, Robert J. ;

Demaria, Sandra ;

Goldstein, Lori ;

Perez, Edith A. ;

Shulman, Lawrence N. ;

Martino, Silvana ;

Wang, Molin ;

Jones, Vicky E. ;

Saphner, Thomas J. ;

Wolff, Antonio C. ;

Wood, William C. ;

Davidson, Nancy E. ;

Sledge, George W. ;

Sparano, Joseph A. ;

Badve, Sunil S. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :2959-+

[2] PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes [J].

Ali, H. R. ;

Glont, S. -E. ;

Blows, F. M. ;

Provenzano, E. ;

Dawson, S. -J. ;

Liu, B. ;

Hiller, L. ;

Dunn, J. ;

Poole, C. J. ;

Bowden, S. ;

Earl, H. M. ;

Pharoah, P. D. P. ;

Caldas, C. .

ANNALS OF ONCOLOGY, 2015, 26 (07) :1488-1493

[3] Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer [J].

Amir, Eitan ;

Miller, Naomi ;

Geddie, William ;

Freedman, Orit ;

Kassam, Farrah ;

Simmons, Christine ;

Oldfield, Maria ;

Dranitsaris, George ;

Tomlinson, George ;

Laupacis, Andreas ;

Tannock, Ian F. ;

Clemons, Mark .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (06) :587-592

[4] Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3 [J].

Andre, Fabrice ;

Hurvitz, Sara ;

Fasolo, Angelica ;

Tseng, Ling-Ming ;

Jerusalem, Guy ;

Wilks, Sharon ;

O'Regan, Ruth ;

Isaacs, Claudine ;

Toi, Masakazu ;

Burris, Howard ;

He, Wei ;

Robinson, Douglas ;

Riester, Markus ;

Taran, Tetiana ;

Chen, David ;

Slamon, Dennis .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (18) :2115-+

[5] Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial [J].

Andre, Fabrice ;

O'Regan, Ruth ;

Ozguroglu, Mustafa ;

Toi, Masakazu ;

Xu, Binghe ;

Jerusalem, Guy ;

Masuda, Norikazu ;

Wilks, Sharon ;

Arena, Francis ;

Isaacs, Claudine ;

Yap, Yoon-Sim ;

Papai, Zsuzsanna ;

Lang, Istvan ;

Armstrong, Anne ;

Lerzo, Guillermo ;

White, Michelle ;

Shen, Kunwei ;

Litton, Jennifer ;

Chen, David ;

Zhang, Yufen ;

Ali, Shyanne ;

Taran, Tetiana ;

Gianni, Luca .

LANCET ONCOLOGY, 2014, 15 (06) :580-591

[6]

[Anonymous], 2015, ASCO ANN M P

[7]

[Anonymous], SAN ANT BREAST CANC

[8] Precision medicine for metastatic breast cancer-limitations and solutions [J].

Arnedos, Monica ;

Vicier, Cecile ;

Loi, Sherene ;

Lefebvre, Celine ;

Michiels, Stefan ;

Bonnefoi, Herve ;

Andre, Fabrice .

NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (12) :693-704

[9] Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance [J].

Arpino, Grazia ;

Wiechmann, Lisa ;

Osborne, C. Kent ;

Schiff, Rachel .

ENDOCRINE REVIEWS, 2008, 29 (02) :217-233

[10] Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy [J].

Arpino, Grazia ;

Gutierrez, Carolina ;

Weiss, Heidi ;

Rimawi, Mothaffar ;

Massarweh, Suleiman ;

Bharwani, Lavina ;

De Placido, Sabino ;

Osborne, C. Kent ;

Schiff, Rachel .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (09) :694-705

← 1 2 3 4 5 6 7 8 9 →